Although entities like the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) state that the available COVID-19 vaccines are safe for everyone over the age of 12, as vaccines are newly developed research is still being conducted into potential adverse effects.
The European Union’s drug regulator said in a statement on Friday that it was unable to confirm if the vaccine produced by drugmaker AstraZenica has the potential to cause blood clots in younger patients and women, as has been reported in some cases.
NTD reported that the European Medicine Agency (EMA) was asked to provide a scientific opinion into the reports of thrombosis with thrombocytopenia syndrome (TTS) following administration of Vaxzevria, the company’s COVID-19 vaccine.
The EMA began looking into the potential for blood clots linked to the vaccine earlier this year when there were reports of such reaction, including deaths, following administration of the shot. Several countries briefly paused using the AstraZenica vaccine over these concerns.
“The evidence did not allow EMA to identify particular risk factors that make TTS more likely,” the regulating body stated this week.
“Although spontaneous reports … have suggested that the risk may be higher in women and in younger adults, and lower after the second compared to the first dose, the limitations of the way the data is collected mean that none of these differences could be confirmed.”
“There is no evidence that delaying the second dose has any influence on the risk of TTS,” a committee tasked with elaborating on the EMA’s findings also stated.
In short: not enough is known to conclude if the vaccine could be linked to blot clots, or if there’s no connection whatsoever, causing the agency to continue to recommend a second dose between four and 12 weeks of receiving the first.
If you appreciate the work we are doing for faith, family, and freedom, please consider a small donation to help us continue. Thank you so much!